v3.26.1
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Reportable Business Segments

Information with respect to these reportable business segments for the three and six months ended June 30, 2026 and 2025 was as follows:

 

Three Months Ended June 30, 2026

 

    Biopharmaceutical
segment		     AI
Infrastructure
and
Technologies
segment		     Consolidated  
Net revenues   $ -     $ -     $ -  
                         
Operating expenses     3,558,843       275,957       3,834,800  
Depreciation and amortization     -       -       -  
Loss from operations     (3,558,843 )     (275,957 )     (3,834,800 )
Interest expense     -       -       -  
Other income     149       -       149  
Loss before provision for income taxes     (3,558,694 )     (275,957 )     (3,834,651 )
Provision for income taxes     -       -       -  
Net loss   $ (3,558,694 )   $ (275,957 )   $ (3,834,651 )

 

Three Months Ended June 30, 2025

 

    Biopharmaceutical
segment		     AI
Infrastructure
and
Technologies
segment		     Consolidated  
Net revenues   $ -     $         -     $ -  
                         
Operating expenses     2,199,649       -       2,199,649  
Depreciation and amortization     -       -       -  
Loss from operations     (2,199,649 )     -       (2,199,649 )
Interest expense     -       -       -  
Other income     173       -       173  
Loss before provision for income taxes     (2,199,476 )     -       (2,199,476 )
Provision for income taxes     -       -       -  
Net loss   $ (2,199,476 )   $ -     $ (2,199,476 )

Six Months Ended June 30, 2026

 

    Biopharmaceutical
segment		     AI
Infrastructure
and
Technologies
segment		     Consolidated  
Net revenues   $      -     $     -     $ -  
                         
Operating expenses     6,207,292       275,957       6,483,249  
Depreciation and amortization     -       -       -  
Loss from operations     (6,207,292 )     (275,957 )     (6,483,249 )
Interest expense     -       -       -  
Realized loss on crypto assets     (44,165 )     -       (44,165 )
Other income     298       -       298  
Loss before provision for income taxes     (6,251,159 )     (275,957 )     (6,527,116 )
Provision for income taxes     -       -       -  
Net loss   $ (6,251,159 )   $ (275,957 )   $ (6,527,116 )

 

Six Months Ended June 30, 2025

 

    Biopharmaceutical
segment		     AI
Infrastructure
and
Technologies
segment		     Consolidated  
Net revenues   $ -     $          -     $ -  
                         
Operating expenses     5,675,666       -       5,675,666  
Depreciation and amortization     -       -       -  
Loss from operations     (5,675,666 )     -       (5,675,666 )
Interest expense     -       -       -  
Other income     354       -       354  
Loss before provision for income taxes     (5,675,312 )     -       (5,675,312 )
Provision for income taxes     -       -       -  
Net loss   $ (5,675,312 )   $ -     $ (5,675,312 )
Schedule of Total Assets by Segment

Total assets by segment on June 30, 2026 and December 31, 2025 were as follows:

 

    June 30,
2026		     December 31,
2025		  
Biopharmaceutical segment   $ 9,584,874     $ 7,603,444  
AI Infrastructure and Technologies segment     -       -  
    $ 9,584,874     $ 7,603,444